Apple Ordered to Pay $184 Million USD More in Masimo Watch Patent Case

Apple has been ordered to pay another $184 million USD to medical technology company Masimo in its long-running Apple Watch patent dispute, pushing the total bill from a $634 million USD jury verdict to about $818 million USD, according to Bloomberg Law.

US District Judge James V. Selna ruled Monday, October 5, 2026, that Masimo is entitled to prejudgment interest on the damages awarded by a California federal jury last year.

Apple had argued that adding interest would amount to a windfall for Masimo. Selna rejected that argument, citing US Supreme Court guidance that interest calculated from when royalty payments should have been received simply compensates a patent owner for money it should have had earlier.

The judge did not give Masimo everything it requested. Masimo sought a 7 percent interest rate, but Selna instead applied the company’s own borrowing rate, compounded annually and measured from when the infringement began.

A federal jury found in November 2025 that Apple infringed Masimo Patent No. 10,433,776 and awarded the company $634 million USD. Selna entered final judgment in July 2026 and rejected Apple’s request for a new trial.

Apple has said the patent expired in 2022 and covers historic patient-monitoring technology, and it plans to appeal the verdict.

The case is separate from Masimo’s dispute with Apple at the US International Trade Commission over blood-oxygen technology. An ITC ruling led to a US import ban on Apple Watch Series 9 and Apple Watch Ultra 2 models in 2023.

Apple later introduced a workaround that moved blood-oxygen processing from the watch to a paired iPhone. An ITC judge found in March 2026 that the redesigned system does not infringe Masimo’s patents.

The restrictions have largely been a US issue, but as Canadians it’s been interesting to follow. Apple Watch models sold in Canada have continued to offer blood-oxygen functionality, so Canadian customers did not face the same feature removal as US buyers, luckily.